Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis

• Conditions: Multiple Sclerosis; EDSS 4-7
• Interventions: Drug: Fampyra

• Registration Number: NCT01720849
• Lead Sponsor: Vestre Viken Hospital Trust

Brief Summary

The aim of the study is to assess improvement in visual evoked potential, cognition, fatigue, micturation and walking impairment under 3 months of Fampyra treatment

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-10-31
• Study First Submitted QC: 2012-11-01
• Study First Posted: 2012-11-02
• Study Start: 2012-12
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-29
• Last Update Posted: 2015-06-30
• Primary Completion: 2016-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

All patients who according to the compound's Norwegian prescription guidelines are deemed eligible for the study, i.e. MS patients with impaired walking as determined by an EDSS 4-7. They do not need a past history of optic neuritis, cognitive failure, fatigue or difficulties micturating.

Exclusion Criteria

MS patients with contraindications to the compound according to the prescription guidelines.

Patients who have been exposed to Fampyra in the past Patients with an MS attack within last 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Fampyra group	Fampyra	-

Primary Outcome Measures

Name	Time	Method
change from baseline in visual evoked potential after 2 weeks and 3 months	5 months

Trial Locations

Locations (1)

Vestre Viken Helseforetak; 🇳🇴 Drammen, Norway